Literature DB >> 18211304

Scrotal ultrasonography: should it be used in routine evaluation of infertile men?

M R Onur1, F Firdolas, R Onur, E Kocakoc, N Akpolat, I Orhan.   

Abstract

Several studies have suggested that male infertility and testicular cancer may have common aetiological factors. Scrotal ultrasonography (US) has an important role in the diagnosis of testicular tumours when not palpable by physical examination. In this study, we present two infertile men referred to our clinic. Patients were evaluated by a detailed physical examination, semen analyses and hormonal assessment. Both patients underwent scrotal US examination. Semen analysis of the patients revealed oligoasthenospermia in both patients. Scrotal US revealed hypoechoic masses in the left and right testes of both patients, which were nonpalpable by physical examination. Scrotal exploration and subsequent orchidectomy were performed. Histopathological examination revealed mixed germ cell tumour and Sertoli-Leydig cell tumour in case 1 and case 2 respectively. With these cases, we discussed the role of scrotal US in the routine diagnostic evaluation of infertile men.

Entities:  

Mesh:

Year:  2008        PMID: 18211304     DOI: 10.1111/j.1439-0272.2008.00812.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  3 in total

Review 1.  Use of Ultrasound in Male Infertility: Appropriate Selection of Men for Scrotal Ultrasound.

Authors:  Joseph M Armstrong; Sorena Keihani; James M Hotaling
Journal:  Curr Urol Rep       Date:  2018-05-28       Impact factor: 3.092

Review 2.  Contemporary diagnostic work-up of testicular germ cell tumours.

Authors:  Klaus-Peter Dieckmann; Ulrich Frey; Guntram Lock
Journal:  Nat Rev Urol       Date:  2013-11-12       Impact factor: 14.432

Review 3.  Prevalence and Management of Incidental Testicular Masses-A Systematic Review.

Authors:  Daniel Henriques; Anabela Mota Pinto; Helena Donato; Ricardo Leão
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.